Dermavant to Present at JMP Securities Life Science Conference
BASEL, Switzerland, June 19, 2018 /PRNewswire/ -- Dermavant today announced that President and Chief Operating Officer Vince Ippolito will present a corporate overview at the JMP Securities Life Science Conference on June 20, 2018 at 2:00 p.m. ET.
About Dermavant
Dermavant is dedicated to developing and, upon regulatory approval, commercializing innovative therapies in medical dermatology. Dermavant currently has five investigational drugs in development: RVT-501, RVT-502, RVT-503, RVT-504, and RVT-201.
RVT-501 is a small molecule phosphodiesterase-4 (PDE4) inhibitor being developed as a topical therapy for patients with mild-to-moderate atopic dermatitis. RVT-502 is a small molecule dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor being developed as a topical therapy for a variety of serious dermatologic conditions including atopic dermatitis. RVT-503 is a preclinical asset with a novel mechanism of action being studied for the treatment of acne. RVT-504 is a combination of a muscarinic antagonist with a muscarinic agonist being developed as an oral therapy for the treatment of hyperhidrosis. RVT-201 is a caspase-1 inhibitor that acts to inhibit the production of inflammatory cytokines and is being developed as a topical therapy for inflammatory skin diseases.
For more information, visit the company website at www.dermavant.com.
Contact
Ric Peterson Chief Financial Officer Dermavant Sciences, Inc. [email protected]
Evermore Cannabis Company, a leader in innovative cannabis cultivation and product development, is thrilled to announce its remarkable success at the first-ever Maryland Leaf Bowl, held on April 13th. Demonstrating excellence across multiple...
Autolomous, the market-leading developer of critical manufacturing management systems for cell and gene therapies, and BioCentriq, industry-leading clinical-phase Cell Therapy CDMO (contract development and manufacturing organization), announce a...
As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art...
The Atrium at Cardinal Drive, a Benchmark Mind & Memory Care community, has ranked among the best assisted living with memory care communities in Massachusetts and the entire U.S. for the second straight year. In U.S. News & World Report's third...
The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) is proud to announce the recipients of the 2024 ADLM and Academy of Diagnostics & Laboratory Medicine Awards. Through this annual awards program, ADLM and its Academy...